Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Neoplasm Metastasis 2Leukemia, Monocytic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Cancer 1

Interventions

fludarabine phosphate 21Cyclophosphamide 20Peripheral Blood Stem Cell Transplantation 19Busulfan 16Tacrolimus 14Whole-Body Irradiation 12Methotrexate 12Mycophenolic Acid 11Cyclosporine 11Antilymphocyte Serum 10fludarabine 6Filgrastim 6peginterferon alfa-2a 5ruxolitinib 4Radiotherapy 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Decitabine 4Aspirin 4Stem Cell Transplantation 3Injections 3Cytogenetic Analysis 3Cytarabine 3Biopsy 3Azacitidine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3merphos 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thrombocythemia, Essential × Liposomes × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡